Theriva Biologics
TOVX
21 hedge funds and large institutions have $272K invested in Theriva Biologics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
54% more capital invested
Capital invested by funds: $177K → $272K (+$95.3K)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
5% more funds holding
Funds holding: 20 → 21 (+1)
0.71% less ownership
Funds ownership: 4.55% → 3.84% (-0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70.8K |
| 2 |
Morgan Stanley
New York
|
+$59.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$49.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$15K |
| 2 |
Jane Street
New York
|
-$14.9K |
| 3 |
Two Sigma Advisers
New York
|
-$11.1K |
| 4 |
Two Sigma Investments
New York
|
-$5.77K |
| 5 |
HF
HRT Financial
New York
|
-$4K |
TOVX Hedge Fund Activity: Q4 2025 in Review
21 of the 8,263 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2025, worth a combined $272K — up 54% from $177K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TOVX positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $70.8K. The largest seller was Virtu Financial, exiting entirely with an estimated $15K sold.
- 21 institutional investors held Theriva Biologics (TOVX) as of Q4 2025, up from 20 in Q3 2025.
- Funds reported $272K of Theriva Biologics stock for Q4 2025, up 54% quarter-over-quarter.
- 7 funds opened new Theriva Biologics positions in Q4 2025 and 6 closed out, a net change of +1 holder.
- The largest Theriva Biologics buyer in Q4 2025 was Vanguard Group, an estimated $70.8K added.
- The largest Theriva Biologics seller in Q4 2025 was Virtu Financial, an estimated $15K sold.
Based on aggregated 13F filings for Q4 2025.